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Abstract
Background: Population-based studies have identified smoking as a pathogenetic factor in chronic periodontitis. At the
same time, chronic periodontal disease has also been found to occur more often in persons suffering from psoriasis than in
controls with no psoriasis. It is known that smoking aggravates both periodontal disease and psoriasis, but so far it has not
been investigated how smoking influences the occurrence and severity of periodontal disease in psoriasis.
Methods: A hospital-based study was conducted to investigate this question. The study population consisted of 82 psoriasis
patients and 89 controls. All patients received a full-mouth periodontal examination, and a published classification based on
bleeding on probing, clinical attachment level and probing depth was utilized for staging. Both patients and controls were
divided into smoker and non-smoker groups, and the resulting groups were compared in terms of periodontal status.
Beyond the descriptive statistics, odds ratios were computed.
Results: Psoriasis in itself increased the likelihood of severe periodontal disease to 4.373 (OR, as compared to non-smoker
controls, p,0.05), while smoking increased it to 24.278 (OR, as compared to non-smoker controls, p,0.001) in the studied
population. In other words, the risk of severe periodontal disease in psoriasis turned out to be six times higher in smokers
than in non-smokers.
Conclusions: The results of this study corroborate those of other studies regarding the link between psoriasis and
periodontal disease, but they also seem to reveal a powerful detrimental effect of smoking on the periodontal health of
psoriasis patients, whereby the authors propose that smoking may have a permissive effect on the development of severe
periodontal disease in psoriasis.
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Introduction
Several chronic illnesses can be traced back to alcohol
consumption, sedentary lifestyle, unhealthy nutrition or smoking.
Smoking, in particular, is a global public health problem [1].
Population-based epidemiological studies have found that peri-
odontal disease is more common in smokers than in nonsmokers
[2,3]. Beyond the obvious explanation that tobacco smoke is a
local irritant, it has been shown that smoking favors colonization
by specific periodontopathic bacteria [4], modulates cellular
immunity [5–7] and favors the development and aggravation of
autoimmune and immune-mediated conditions [8,9], including
psoriasis [10]. Smoking, therefore, appears to be a risk factor for
both periodontal disease and psoriasis. What is more interesting is
that psoriasis and periodontal disease seem to be associated
themselves. It was Yamada and colleagues in 1992 who first
reported a case of psoriasis in which exacerbation of the cutaneous
disease was accompanied by gingival epithelial changes and
periodontal bursts [11], but the first blinded, case-controlled study
on the assumed association was published only eighteen years later
by Preus and colleagues [12]. This was the first study to seriously
raise the issue of the possible association between the two
conditions, followed by the studies of Lazaridou et al. [13] and
Keller and Lin [14], both of which corroborated the findings of the
Preus group.
It is established that the immunopathogenesis of psoriasis [15]
and the aggravation of periodontal disease [16] is linked to altered
T- lymphocyte - mediated immunity. Periodontal disease turns
progressive when B-cell/plasma cell responses become dominant
in the periodontal inflammatory process, which is preceded by the
oligoclonal expansion of Th2 lymphocytes. These lymphocytes
stimulate B-cells and induce humoral immune responses by
secreting interleukins IL-4, IL-5 and IL-10 (see Table 1). It is to
be noted that Th1 cells are also capable of stimulating B cells by
secreting INF-c. This can be an alternative way of shifting the
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immune response toward B cell dominance, especially in the
context of suppressed T cell responses (as it happens in the
oligoclonal expansion of Th2 cells). Th1 cells are stimulated by IL-
6, IL-8, IL-12, IL-18, TNF-a and INF-c, the levels of all of which
were found to be elevated in the serum of patients with chronic
plaque psoriasis [17]. It might not be too far-fetched to
hypothesize that psoriasis can aggravate periodontal disease
because enhanced Th1 INF-c secretion furthers the effects of
Th2 dominance. However, the elaborate examination of the
connection between periodontal disease and psoriasis is no subject
of this study.
As tobacco smoking also interferes with immunity, favors
colonization by periodontopathic bacteria and acts as a local
irritant, we hypothesized that smoking may act as a trigger or
permissive factor of periodontal disease in patients suffering from
psoriasis. To test this hypothesis, the prevalence and severity of
periodontal disease was assessed in a group smoking and non-
smoking psoriasis patients and a group of smoking and non-
smoking psoriasis-free controls. The specific question we sought an
answer to was whether periodontal disease occurs more often and
in a more serious form in smoking psoriasis patients than in non-
smoking psoriasis patients. The primary aim of the study,
therefore, was to find evidence for or against the hypothesized
permissive role of smoking.
Methods
Ethics statement
The study was approved by the Human Ethics Review Board of
the University of Szeged (approval Nos. 2848 and 2879), and the
study design conformed to the Declaration of Helsinki in all
respects. Written informed consent was obtained from all
participants.
Protocol and Study Participants
A hospital-based case-control study was conducted in 2012.
Participants (n = 82) were selected from the patients of the Psoriasis
Outpatient Unit of the Department of Dermatology and
Allergology, University of Szeged. The control group (n= 89)
was recruited from people attending mandatory lung screening in
the same city and the same period, on a voluntary basis. Controls
were age-matched to patients, but the sex ratios were also almost
identical (see Table 2.). Required sample size was calculated with
G*Power 3.1.5. (University of Kiel, Germany), a software designed
especially for statistical power and sample size computation [18].
The software allows the computation of achieved statistical power
(post-hoc) and required sample size (a priori). As mostly categorical
variables were to be analyzed, a priori sample size estimation was
performed for crosstabs/chi square/contingency tables, with the
following input parameters: effect size (w): 0.5; a: 0.05;power (1-b):
0.85; DF: 3. Required sample size turned out to be n= 50, but
much more cases were available, whereby, also expecting dropout,
it was decided that 100 cases and 100 controls would be examined.
This way, even with the dropout of 18 cases and 11 controls, a
statistical power over 0.9 was achieved.
Patients were eligible for the study if they were diagnosed with
psoriasis (defined as ICD-10 L40.0-L40.9) by a dermatologist. The
diagnosis of psoriasis was set up earlier than the beginning of this
study in all cases, whereby dermatological examination was not
regarded as a direct part of this study, neither was it listed on the
informed consent forms as such. Exclusion criteria for both groups
were determined based on the literature of the subject and
included obesity (BMI$30), excessive alcohol consumption, drug
abuse, diabetes mellitus, oestrogen deficiency, diseases causing
neutropenia and local or systemic inflammatory conditions (other
than psoriasis) [19,20]. Dropout resulted partially from meeting
one or more of the exclusion criteria (especially excessive self-
reported alcohol consumption), but there were subjects who quit
by their own will before the intraoral examinatiom, and a number
of subjects failed to provide tobacco use data.
Demographic and tobacco use data were collected by a
questionnaire. Medical information on both controls and psoriasis
patients was extracted from patient files and hospital records.
Participants were divided into smoker and non-smoker groups,
Table 1. The applied clinical staging and the corresponding pathological/pathophysiological changes.
CLINICAL STAGING PATHOLOGY/PATHOPHYSIOLOGY
(Fernandes et al., 2009) (Ohlrich et al., 2009)
1.NO CLINICAL SIGNS- no clinical attachment loss (CAL) or
bleeding on probing (BOP)
(NO LESION- NOT CLASSIFIED EXPLICITLY IN OHLRICH ET AL.)
(GINGIVITIS-NOT CLASSIFIED EXPLICITLY IN FERNANDES ET AL.)
(CPITN 1)
1. INITIAL LESION – up to 4 days following plaque accumulation. Polymorphonuclear
leukocytes (PMN), complement activation, loss of connective tissue. Mast cells release
tumor necrosis factor alpha, PMNs migrate into the gingival sulcus, but as the bacteria
are protected by the biofilm, abortive phagocytosis occurs. PMNs release lysosomal
contents, which leads to further tissue destruction.
2.EARLY PERIODONTITIS- CAL
$1 mm in $2 teeth
(CPITN 2)
2.EARLY/STABLE LESION- 7-21 days after plaque accumulation, clinically evident
approximately from day 12. Dominantly macrophages and lymphocytes (CD4+:CD8+ 2:1).
Perivascular inflammatory infiltrate. Intercellular spaces between epithelial cells widen,
bacterial products infiltrate the gingival tissues at a higher rate. Escalation of response. If
plaque removed, tissue remodeling can take place.
3.MODERATE PERIODONTITIS- 3 sites with CAL $4 mm and
at least 2 sites with probing depth (PD) $3 mm
(CPITN 3)
3. ESTABLISHED OR PROGRESSIVE LESION- dominantly a B cell/plasma cell
response. High levels of IL-1 and IL-6: connective tissue loss, breakdown of bone.
4. SEVERE PERIODONTITIS- CAL $6 mm in $2 teeth and PD
$5 mm in $1 site
(CPITN 4)
4. ADVANCED LESION- Overt loss of attachment. High levels of IL-1, TNF a and PGE2
stimulate fibroblasts and macrophages to produce matrix metalloproteases. The
junctional epithelium progresses in apical direction (deepening periodontal pocket).
Oligoclonal Th2 (CD4
+) dominance.
The approximate CPITN stage is also given (in brackets).
doi:10.1371/journal.pone.0092333.t001
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based on their self-reported current tobacco use. To minimize
desirable response tendency in this crucial aspect, smoking was not
pointed out to the participants as the target variable until all study
procedures had been finished.
The clinical staging of periodontal disease is still a matter of
debate, even though the progression of the disease is well
established in pathological terms [16]. The most widely used
classification is the Community Periodontal Index of the WHO
(CPITN) [21]. Applicable as it may be for clinical purposes,
CPITN defines rather wide categories, which carries the risk of
oversampling. Therefore we decided to use the more detailed (and
thus more strict) staging proposed by Fernandes and colleagues
[22]. The staging requires the following parameters to be
recorded: the number of missing teeth (excluding third molars),
Plaque Index (PI; also known as the Silness-Lo¨e Index), bleeding
on probing (BOP; the presence or absence of bleeding within 15
sec after probing), probing depth (PD; in millimeters), and clinical
attachment level (CAL; to describe the position of the soft tissue in
relation to the cemento-enamel junction ).
Clinical Examination
In order to record the above mentioned parameters, all patients
received a full mouth periodontal examination, performed by a
periodontist. BOP, PD and CAL were examined six sites per tooth
(mesio-buccal, buccal, disto-buccal, disto-lingual, lingual, mesio-
lingual), with the exception of third molars. Williams probes (Hu-
Friedy Manufacturing Co., Chicago, USA) were used. Table 1
shows the categories of the applied staging and the corresponding
pathological/pathophysiological status.
Statistical Analysis
The study and control groups were compared by smoking
status. To express the probability that a member of a given group
develops a given clinical degree of periodontal disease, multino-
mial logistic regression was conducted and the odds ratios were
calculated. In the multinomial model, disease severity (healthy,
early, moderate, severe) was defined as the outcome variable,
smoking status (smoker or non-smoker), and group (psoriasis or
control) were defined as factors, and smoking intensity (expressed
as the number of cigarettes smoked per day) was defined as a
covariate. Descriptive statistics and odds ratios were calculated in
SPSS 17.0 (SPSS, Inc., Chicago, USA).
Results
The population
Table 2. shows the descriptive statistics of both the study and the
control groups. Females were slightly over-represented in the
psoriasis group (nfemale = 45,nmale = 37) while in the control group
the sexes were represented almost perfectly equally (nfemale = 44,
nmale = 45). Crosstab analysis with x
2 test was conducted to find
out if sex was significantly associated with disease severity, but the
association turned out to be non-significant for both patients (x2
= 5.184 p= 0.189) and controls (x2 = 3.029, p = 0.387), whereby
sex was not included in the multinomial regression. Patients and
controls were age-matched (mean age for the entire sample: 50.6
years). The division into four groups by diagnosis (psoriasis or
control) and smoking status (yes or no) for the purposes of the
analysis did not change these parameters significantly, that is, the
ratios remained representative of the whole sample. Group
membership (i.e. patient or control) was shown to be significantly
associated with disease severity (x2 = 27.337, p = 0.000).
In the psoriasis group 35 persons defined themselves as smoker
(43%). The number of smokers was lower among the control
group, only 24 persons defined themselves as smoker (27%). In the
psoriasis+smoker group no patient could be categorized as
periodontally healthy. 14% of this group had early, 37% moderate
and 49% severe periodontal disease. Among non-smoker patients
21% were classified as healthy, 28% as having early, 39% as
having moderate and 12% as having severe periodontal disease.
42% of smoking controls was periodontally healthy, 33% had
Table 2. Descriptive statistics of the study and control groups with the characteristics of the subsamples.
PSORIASIS CONTROL
Age (mean±SD, years) 50.9613.4 50.3613.7
smoker subsample 48.5614.0 43.3612.4
nonsmoker subsample 54.7612.9 52.9614.7
Sex ratio F:M (n(%):n(%)) 45(55%):37(45%) 44(49%):45(51%)
smoker subsample 24(60%):21(40%) 12(50%):12(50%)
nonsmoker subsample 23(49%):24(51%) 33(51%):32(49%)
Smoking (n(%)) 35(43%) 24(27%)
Periodontal status in smokers (n) healthy: - reference category healthy: 10
early: 5 p,0.001 early: 8
moderate: 13 p,0.001 moderate: 4
severe: 17 n.s. severe: 2
Periodontal status in healthy: 10 reference category healthy: 25
nonsmokers (n) early: 13 n.s. early: 19
moderate: 18 p = 0.05 moderate: 17
severe: 6 p,0.05 severe: 4
To keep the table transparent, percentages have been rounded to whole numbers. Note that no periodontally healthy smoker psoriasis patients were found. A trend
analysis (x2 with adjusted residuals) revealed a significant trend (x2 = 48.074, p = 0.000), with non-smoker controls being the less likely to have any stage of periodontal
disease and smoker patients being the most likely to have the severe stage. Significance values refer to the comparison of odds with healthy as the reference category
(see also Table 3.).
doi:10.1371/journal.pone.0092333.t002
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early, 17% moderate and 8% severe periodontal disease.
Nonsmoking controls were periodontally healthy in 38%, 29%
had early periodontal disease, while in 26% of the cases the disease
presented in its moderate and in 7% in its severe form. These data
reflect opposing tendencies between smoker patients and non-
smoker controls, that is, while in the smoker patient subsample the
severe stage of periodontal disease is the most frequent, and no
periodontally healthy patient is seen, in the non-smoker control
subsample exactly the opposite can be observed (Figure 1.).
Smoking history and smoking intensity
In terms of smoking history (expressed in years) and their
intensity of smoking (expressed as the number of cigarettes smoked
per day), controls and psoriasis patients turned out to be quite
similar. Smoking controls had smoked for a mean of 20.9 years
(mode: 20 years, SD: 11.97), and they smoked a mean of 16
cigarettes a day (mode: 20 cigarettes, SD: 11.67). Smoking patients
had smoked for an average of 16.57 years (mode: 20 years, SD:
12.37), and they smoked an average of 13 cigarettes a day (mode:
20 cigarettes, SD: 8.57). Indeed, the two groups exhibited no
statistically significant difference in either of these parameters
(MWU=315, n1= 35, n2= 24, p = 0.17, years; MWU=758,
n1= 35, n2= 24, p= 0.57, cigarettes). The crosstab analysis
revealed that smoking status in itself was significantly associated
with disease severity only in patients (x2 = 18.258, p= 0.000). In
controls, no significant association was seen (x2 = 0.935,
p = 0.812). However, when the data were re-coded so that the
outcome variable was not disease severity, but the occurrence of
any stage of the disease, the association was highly significant (x2 =
89.000, p = 0.000). As for smoking history and intensity, the built-
in likelihood ratio test of the multinomial logistic regression
module of SPSS revealed that smoking history had a significant
effect on disease severity (x2 = 11.099, p = 0.011), but the effect of
smoking intensity was not significant (x2 = 30.862, p = 0.504).
Odds Ratios
Odds ratios with significance and confidence intervals are given
in Table 3. Odds ratios were calculated in a multinomial logistic
regression model. Smokers and controls were compared stagewise,
according to the applied classification. The factors of the model
were smoking status (smoker or non-smoker) and group (patient or
control), and the covariate was smoking history (in years). Five
comparisons were done, that is, non-smoker controls were
compared with smoker controls (OREARLY: 1.053, ORMODERATE:
0.588, ORSEVERE: 1.250 ), with non-smoker patients (OREARLY:
1.944, ORMODERATE: 2.647, ORSEVERE: 4.373 ) and with smoker
patients (OREARLY: 1.711, ORMODERATE: 2.500, ORSEVERE: 24.278),
smoker patients were also compared with non-smoker patients
(OREARLY: 6.082, ORMODERATE: 1.712, ORSEVERE: 4.480 ), and smoker
controls were compared with smoker patients (OREARLY: 1.904,
ORMODERATE: 9.900, ORSEVERE: 2.589 ). Significantly higher odds of
developing moderate (p = 0.05) and severe (p,0.05) periodontal
disease were found when non-smoker patients were compared
against non-smoker controls (the periodontal risk of psoriasis
alone). The highest odds ratio resulted from the comparison of
smoker patients with non-smoker controls (24.278, p,0.001),
which is 4.43 times higher than the combination of the individual
odds of smoking (1.250, n.s.) and psoriasis (4.373, p,0.05). It must
be noted, though, that the high odds ratio had a rather wide
confidence interval. When compared with non-smoker patients,
smoker patients’ odds of developing periodontal disease was
significantly higher at all three stages (p,0.001). Finally, as
compared to smoker controls, smoker patients’ odds of developing
early or moderate periodontal disease were also significantly
higher (p,0.001), but no significant difference was observed
regarding the severe stage of the disease.
The covariate smoking history was significantly associated with
disease severity in both patients (x2 = 12.204, p = 0.014) and
controls (x2 = 9.869, p = 0.02). The odds ratios were positive for
the moderate and severe stages in both groups (ORCONTROL,
MODERATE: 1.145, CI:0.999–1.312; ORCONTROL, SEVERE: 1.164, CI:
0.963–1.408; ORPATIENT, MODERATE: 1,112, CI: 0.939–1.318; ORPA-
TIENT, SEVERE:1.185, CI: 0.998–1.406), indicating that a longer
smoking history significantly increases the odds that the moderate
or severe stage of the disease occurs, as compared to the early
stage.
Figure 1. Opposing tendencies: while in the smoker patient subsample the severe stage of periodontal disease was the most
frequent, and no periodontally healthy patient was seen, in the non-smoker control subsample exactly the opposite was observed.
doi:10.1371/journal.pone.0092333.g001
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Discussion
In the present study it was demonstrated that psoriasis patients
who smoke are at an approximately sixfold higher risk of
developing severe periodontal disease, as compared to psoriasis
patients who do not smoke. Psoriasis in itself increases the
likelihood of severe periodontal disease to 4.373 (as compared to
non-smoker controls), while smoking appears to increase this to
24.278. In other words, the risk of severe periodontal disease in
psoriasis is approximately six times higher in smokers than in non-
smokers. It would be reasonable to infer that this increase in risk is
merely the result of the individual risk factors adding up. To test
that possibility, odds ratios were combined and the synergy factor
was calculated.
Combined odds expresses the probability of a given condition if
all combined risk factors are present. For samples of similar size,
combination of odds is done by averaging their logs (logOR1/
logOR2). For psoriasis alone (4.373) and smoking alone (1.250), the
combined odds of severe periodontal disease is 6.60, far below the
observed 24.278. From this it may be conferred that what is
observed in smoker patients is not simply the odds of psoriasis and
smoking added up. Computation of the synergy factor corrobo-
rates this suspicion. The synergy factor was devised by Borja and
co-workers [23] to allow the estimation of whether two factors are
in a positive or negative interaction in terms of bringing about a
given condition, based on their individual odds. The factor is
calculated as SF =OR12/(OR16OR2), where OR12 expresses the
combined odds of the examined factors. SF= 1 expresses the
simple addition of the odds, SF,1 means negative interaction
(antagonism) and SF.1 denotes positive interaction (synergy). The
value of the synergy factor for the odds of psoriasis and smoking is
1.2, indicating a synergistic effect. It seems, therefore, that smoking
acts as a permissive factor.
It was also found that the association between smoking status
and disease severity is significant only in the patient group, which
is also to support that exposure to cigarette smoke and psoriasis act
together toward the aggravation of periodontal disease. The lack
of significant association, however, should not be interpreted as
evidence that cigarette smoke alone does not cause periodontal
disease. Evidence suggests that it does [24], and the additional
analysis also showed that when the target variable is the
occurrence of periodontal disease, the association is highly
significant. From this it might be inferred, that smoking increases
the odds of periodontal disease in both controls and psoriasis
patients, but psoriasis patients are perdisposed to the more severe
forms of the disease.
A further interesting result is the significant association of
smoking history with the occurrence of the moderate and severe
forms of periodontal disease in both groups. Together with the
lack of significant association with the number of cigarettes
smoked per day, it suggests that the key factor in the proposed
permissive role of cigarette smoke is chronic exposure, apparently
regardless of how heavy a smoker one is.
As no study before has dealt with the effects of smoking on
periodontal disease severity in psoriasis, it is beyond our limitations
to give an exact explanation of these findings. However, enough is
known about the pathogenesis of psoriasis and periodontal disease
and the pathophysiological effects of smoking to allow the
articulation of the elements of a hypothesis, which we briefly
delineate here.
As pointed out by Ohlrich and co-workers, the most readily
observable difference between the early and later stages of
periodontal disease is that in the later stages the inflammatory
response is dominated by B lymphocytes, instead of T lymphocytes
[16]. It is in the context of this exaggerated and maladaptive B
cell/plasma cell response that periodontal dissue destruction and
Table 3. Odds ratios by clinical staging.
COMPARISON STAGE OR Sig. 95% CI (lower;upper)
SMOKER CONTROLS (vs. non-
smoker controls)
early 1.053 n.s. 0.394;3.177
moderate 0.588 n.s 0.158;2.187
severe 1.250 n.s 0.197;7.942
NON-SMOKER PATIENTS (vs.
non-smoker controls)
early 1.944 n.s. 0.706;5.353
moderate 2.647 p= 0.05 0.985;7.113
severe 4.373 p,0.05 1.114;17.169
SMOKER PATIENTS (vs. non-
smoker controls)
early 1.711 n.s 0.618;4.732
moderate 2.500 n.s 0.924;6.761
severe 24.278 p,0.001 5.207;113.189
SMOKER PATIENTS (vs. non-
smoker patients)
early 6.082 p,0.001 1.516;2.440
moderate 1.722 p,0.001 3.535;3.689
severe 4.480 p,0.001 1.651-6.851
SMOKER PATIENTS (vs.
smoker controls)
early 1.904 p,0.001 1.202; 3.016
moderate 9.900 p,0.001 1.568;6.262
severe 2.589 n.s. 2.108;2.695
In each case, the ratios express the odds that a member of the given category (printed in capitals) develops the given stage of periodontitis in comparison with the
members of another category (in brackets). Significance levels and 95% confidence intervals (with lower and upper limits) are also given.
doi:10.1371/journal.pone.0092333.t003
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bone breakdown occurs. Our propsed hypothesis, therefore,
centers around this T-to-B shift, which appears to be the key
event in the aggravation of periodontal disease, and how cigarette
smoke might play a permissive role in the process. Here we
concentrate only on a putative immunological backrgound, while
we understand that additional factors, like the detrimental effect of
smoking on gingival circulation [25,26] can also contribute to the
end result.
It is well established that psoriasis is associated with a millieu of
inflammatory mediators that favors a shift toward B cell responses.
Serum levels of the inflammatory mediators IL-6, IL-8, IL-12, IL-
18, TNF-a and INF-c were found to be elevated in plaque
psoriasis [17]. These mediators are all documented to activate B
cells [27–30]. TNF-a is also a potent stimulant of fibroblasts and
macrophages, which, upon activation, release matrix metallopro-
teases [16]. As mentioned before, periodontal disease itself is
associated with Th2 expansion. This, on one hand, suppresses T
cell responses, but Th2 cells, in the presence of antigen, can
stimulate B cells too [31]. Therefore, it might be argued that
psoriasis increases susecptibility to destructive immune responses
in general by shifting the immune response profile toward B cell
responses, which would explain the original observation - also
corroborated by this study- that patients with psoriasis develop
periodontal disease more often than psoriasis-free individuals.
How, then, might cigarette smoke boost this effect? We propose
that toll-like receptor 4 (TLR 4) can play a key role here. Toll-like
receptors are preferentially expressed on immune cells, and
mediate immune responses. TLR4 on the surface of Th1 cells
activate these cells upon binding to bacterial lipopolysaccharides to
secrete INF-c, a potent B cell activator [32]. Normally, this is part
of the immune response to bacterial colonization of the gingival
sulcus. However, if TLR 4 is overexpressed, the response may
become exaggerated and maladaptive. Pace and co-workers
demonstrated that cigarette smoke causes upregulation of TLR4
in airway epithelial cells of smokers with COPD, and they
proposed that this upregulation might be the reason why a
dominantly Th1-regulated immune response is seen in the airways
of COPD patients [33]. The authors also demonstrated that
cigarette smoke increased epithelial cells’ ability to bind bacterial
lipopolysaccharides [33]. TLR4 upregulation was demonstrated in
the psoriatic skin too [34]. It is not known if cigarette smoke has
the same effect in the periodontal tissues (and on the surface of
Th1 cells), but it seems plausible to assume that TLR 4
upregulation can be the key step in the destructive T- to B- shift
in periodontal disease in the context of an already B-biased
inflammatory mediator environment. Based on the literature, we
propose that the examination of the effects of cigarette smoke on
TLR4 expression in the gingival tissues could be a logical next step
toward the understanding of our observations.
Conclusions
The results of this study corroborate those of other studies
regarding the link between psoriasis and periodontal disease, but
they also seem to reveal a powerful detrimental effect of smoking
on the periodontal health of psoriasis patients, whereby we
propose that smoking might have a permissive effect on the
development of severe periodontal disease in psoriasis. It seems
plausible to propose that smoking exerts this effect through the
upregulation of TLR-4, but this cannot be decided without further
research, as at the moment no data are available regarding the
periodontium.
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